Home/Chugai Pharmabody Research/Hideaki Shimada, Ph.D.

HS

Hideaki Shimada, Ph.D.

Chairman

Chugai Pharmabody Research

Therapeutic Areas

Oncology Immunology Hematology Infectious Disease

Chugai Pharmabody Research Pipeline

Drug	Indication	Phase
CPR‑PNH‑001	Paroxysmal Nocturnal Hemoglobinuria	Approved
CPR‑DEN‑001	Dengue Virus Infection	Preclinical
CPR‑COV‑001	COVID‑19	Preclinical
CPR‑CYC‑101	Solid Tumors	Preclinical
CPR‑CYC‑202	Inflammatory Diseases	Preclinical

Leadership Team at Chugai Pharmabody Research

Futa Mimoto, Ph.D.

Dr. Yuki Tanaka

Chief Scientific Officer

View full Chugai Pharmabody Research profile